Prolynx, LLC

SAN FRANCISCO, CA 94117

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $1.34MM
First Award Date 05/21/10
Most Recent Award Date 09/20/17

Key Personnel

Last Name Name Awards Contact
Ashley Gary W Ashley 6 Message
Santi Daniel V Santi 1

5 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 09/20/17 - 09/17/18

We have developed a chemically-controlled ultra-long acting delivery system to support once- weekly to once-monthly administration of peptides. In this system, the peptide is covalently attached to a hydrogel microsphere depot by a cleavable ?-eliminative linker; upon subcutaneous injection, the linker slowly cleaves and releases the drug. If th...

Phase 2 SBIR

Agency: National Science Foundation
Topic: BC
Budget: 11/10/14 - 04/30/17

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is an improvement in public health and quality of life through improved methods of medicinal therapy. The technology developed in this project is aimed at improving the effectiveness of existing therapeutic drugs while facilitating their use...

Phase 1 SBIR

Agency: National Science Foundation
Topic: BC-2012
Budget: 01/01/13 - 12/31/13

This Small Business Innovation Research Phase I project seeks to develop novel hydrogel drug-delivery systems. We have developed linkers for drug conjugation to circulating macromolecules that release the native drug by beta-eliminative cleavage at predictable rates with half-lives spanning hours to months, and do not require enzymes. However, a...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 07/10/10 - 06/30/11

DESCRIPTION (provided by applicant): We are developing a platform technology that allows predictable, controlled release of drugs from macromolecule-drug conjugates. In one current format, PEG of sufficient size to have prolonged blood circulation times is attached to the drug by linkers designed to release the native drug at predictable and con...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 05/21/10 - 10/31/10

DESCRIPTION (provided by applicant): Many potent and specific peptides suffer problems of short or sub-optimal duration. A possible solution to such problems involves conjugation to macromolecules such as polyethylene glycol (PEG) that are slowly eliminated from the body, and thus prolongs the action of the attached peptide. For peptide therapeu...